b1a

Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.

Ivermectin B1a monosaccharide is produced by selective hydrolysis of the terminal saccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity. This compound has been used as a probe to detect some types of ivermectin resistance.

Avermectin B1a is a macrocyclic lactone disaccharide anthelmintic agent .

epi-Ivermectin B1a is a significant impurity related to Ivermectin, typically found as a process-related impurity or potential degradation product in antiparasitic formulations. It is also utilized in research on both in vivo and in vitro parasites in cattle.

Avermectin B1 is served as anthelmintic and insecticide.

2-epi-Abamectin, a degradation product of abamectin, exhibits toxicity towards the two-spotted spider mite in contact assays, possessing an LC50 value of 4 ppm. This indicates it is approximately 100-fold less potent than its precursor, abamectin.

8a-OH-Avermectin B1a is a primary mono-oxidation degradation product generated during the photodegradation of Avermectin B1a. 8a-OH-Avermectin B1a is useful for research on antiparasitic infections.

Eprinomectin B1a, composing over 90% of the antiparasitic agent eprinomectin, is a primary component alongside eprinomectin B1b, which constitutes less than 10%. This compound is part of the avermectin family, used as insecticides and anthelmintics.

Avermectin B1a in Acetonitrile (Standard) is a standard material used for research and analysis of Avermectin B1a. Avermectin is a compound that inhibits the expression of Caspase-8 and Bcl-2.

8,9-Z-Abamectin B1a is the 8,9-Z-isomer of Abamectin B1a. Avermectin B1a serves as an anthelmintic agent, capable of paralyzing nematodes.

Δ²-Avermectin B₁ₐ (Compound 3) is an antiparasitic agent that specifically targets glutamate-gated chloride channels (GluCls) in the neuromuscular systems of invertebrates. By increasing chloride ion influx, it causes depolarization of neuromuscular cell membranes, inhibiting neural signal transmission, which ultimately paralyzes and kills the parasite. It shows potential for research in agricultural pest control.

Ivermectin B1a aglycone is an acid degradation product produced by hydrolysis of the disaccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity.

Avermectin B1a aglycone is an aglycone form of the anthelmintic and insecticide avermectin B1a . It hyperpolarizes P. crassipes muscle fibers with a minimum active concentration (MAC) value of 0.1 μM. Avermectin B1a aglycone decreases survival of C. elegans (MAC = 0.1 μM). In vivo, avermectin B1a aglycone prevents seizures induced by pentylenetetrazole in mice (ED50 = 43.9 mg/kg) without inducing deficits in rotarod performance.

Avermectin B1a monosaccharide is a macrolide anthelmintic and monosaccharide form of avermectin B1a . It is lethal to C. elegans with a minimum active concentration (MAC) value of 0.1 μM. Avermectin B1a monosaccharide also stimulates conductance in isolated shore crab muscle.

Emamectin B1a can be used in relevant research in the life sciences. Its product number is T37663 and CAS number is 121124-29-6.

Ivermectin B1a-d2-1 is the deuterium-labeled form of Ivermectin B1a. As a derivative of Avermectin B1a, Ivermectin B1a constitutes the primary component of Ivermectin. Ivermectin (MK-933) is a broad-spectrum antiparasitic agent and is also being considered as a candidate active molecule in the treatment of SARS-CoV-2/COVID-19.

Deuterated ivermectin B1a

Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp.

CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disorders, psychosis, and cardiovascular.

CB1 antagonist 2 (AM4113) is caimabinoid 1 (CB1) antagonist which inhibits CB1 in vivo with an IC50 of 25.5 nM.

ABCB1/ABCG2-IN-1 (Compound (S,Z)-4b) is an inhibitor of ABCB1 and ABCB2 transport proteins. It exhibits moderate activity against SW620M, -V, and -Mito variants with an IC50 of approximately 50 μM. In vitro, ABCB1/ABCG2-IN-1 can influence methotrexate resistance and is applicable in cancer research.

CB1 antagonist6 (Compound 11jE2) is an orally active CB1R antagonist with an IC50 value of 23 nM. It significantly reduces food intake and body weight in diet-induced obesity (DIO) mice, improves glucose tolerance and insulin resistance, and lowers serum ALT and AST levels, demonstrating hepatoprotective effects. CB1 antagonist6 is applicable for studies on metabolic syndrome, including obesity and diabetes.

Pim1/AKK1-IN-1 (LKB1/AAK1 dual inhibitor) is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively, and also inhibits MPSK1 and TNIK.